These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31685767)

  • 1. Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1).
    Konaka K; Sakurada T; Saito T; Mori S; Imanishi M; Kakiuchi S; Fushitani S; Ishizawa K
    Biol Pharm Bull; 2019; 42(11):1839-1845. PubMed ID: 31685767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer.
    Fujii H; Yamada Y; Watanabe D; Matsuhashi N; Takahashi T; Yoshida K; Suzuki A
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):123-129. PubMed ID: 30377777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.
    Sugiyama T; Hirose T; Kusumoto S; Shirai T; Yamaoka T; Okuda K; Ohnishi T; Ohmori T; Adachi M
    Oncol Res; 2010; 18(7):337-42. PubMed ID: 20377135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis.
    Ando Y; Saka H; Ando M; Sawa T; Muro K; Ueoka H; Yokoyama A; Saitoh S; Shimokata K; Hasegawa Y
    Cancer Res; 2000 Dec; 60(24):6921-6. PubMed ID: 11156391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. UGT1A1 Gene Polymorphisms in Patients with Small Cell Lung Cancer Treated with Irinotecan-Platinum Doublet Chemotherapy and Their Association with Gastrointestinal Toxicity and Overall Survival.
    Bandyopadhyay A; Sharma S; Behera D; Singh N
    Oncologist; 2021 Aug; 26(8):701-713. PubMed ID: 33728696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weekly regimen of irinotecan/docetaxel in previously treated non-small cell lung cancer patients and correlation with uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism.
    Font A; Sánchez JM; Tarón M; Martinez-Balibrea E; Sánchez JJ; Manzano JL; Margelí M; Richardet M; Barnadas A; Abad A; Rosell R
    Invest New Drugs; 2003 Nov; 21(4):435-43. PubMed ID: 14586211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Correlation between nUGT1A1 gene polymorphisms and adverse events of irinotecan plus S-1 for patients with recurrent or metastatic esophageal squamous cell carcinoma: a prospective, open-label, randomized controlled trial (ESWN 01)].
    Wang X; Liu Y; Huang JX; Lu P; Ba Y; Wu L; Bai YX; Zhang S; Feng JF; Cheng Y; Li J; Wen L; Yuan XL; Ma CW; Hu CH; Fan QX; Xu BH; Huang J
    Zhonghua Zhong Liu Za Zhi; 2021 Nov; 43(11):1177-1182. PubMed ID: 34794220
    [No Abstract]   [Full Text] [Related]  

  • 8. UDP-glucuronosyltransferase 1A1*6 and *28 polymorphisms as indicators of initial dose level of irinotecan to reduce risk of neutropenia in patients receiving FOLFIRI for colorectal cancer.
    Miyata Y; Touyama T; Kusumi T; Morita Y; Mizunuma N; Taniguchi F; Manabe M
    Int J Clin Oncol; 2016 Aug; 21(4):696-703. PubMed ID: 26710796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between UGT1A1 gene polymorphism and safety and efficacy of irinotecan monotherapy as the third-line treatment for advanced gastric cancer.
    Yamaguchi T; Iwasa S; Shoji H; Honma Y; Takashima A; Kato K; Hamaguchi T; Higuchi K; Boku N
    Gastric Cancer; 2019 Jul; 22(4):778-784. PubMed ID: 30603911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic advantage of irinotecan dose escalation according to uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) genotyping in patients with metastatic colorectal cancer treated with bevacizumab combined with 5-fluorouracil/leucovorin with irinotecan in a first-line setting.
    Lu CY; Huang CW; Hu HM; Tsai HL; Huang CM; Yu FJ; Huang MY; Chang SF; Huang ML; Wang JY
    Transl Res; 2014 Aug; 164(2):169-76. PubMed ID: 24462762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).
    Fukuda M; Shimada M; Kitazaki T; Nagashima S; Hashiguchi K; Ebi N; Takayama K; Nakanishi Y; Semba H; Harada T; Seto T; Okamoto I; Ichinose Y; Sugio K
    Thorac Cancer; 2017 Jan; 8(1):40-45. PubMed ID: 27883280
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of UGT1A1 genetic polymorphism on toxicity in unresectable pancreatic cancer patients undergoing FOLFIRINOX.
    Shirasu H; Todaka A; Omae K; Fujii H; Mizuno N; Ozaka M; Ueno H; Kobayashi S; Uesugi K; Kobayashi N; Hayashi H; Sudo K; Okano N; Horita Y; Kamei K; Yukisawa S; Kobayashi M; Fukutomi A
    Cancer Sci; 2019 Feb; 110(2):707-716. PubMed ID: 30447099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity.
    Kitagawa C; Ando M; Ando Y; Sekido Y; Wakai K; Imaizumi K; Shimokata K; Hasegawa Y
    Pharmacogenet Genomics; 2005 Jan; 15(1):35-41. PubMed ID: 15864124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased frequency of uridine diphosphate glucuronosyltransferase 1A1 7/7 in patients experiencing severe irinotecan-induced toxicities.
    Fakih MG; Ross ME; Starostik P
    Clin Colorectal Cancer; 2007 Jul; 6(8):583-7. PubMed ID: 17681105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uridine diphosphate glucuronide transferase 1A1FNx0128 gene polymorphism and the toxicity of irinotecan in recurrent and refractory small cell lung cancer.
    Yun F; Lulu M; Zhiyu H; Lei G; Haifeng Y; Tao L; Haiyan Y; Conghua X
    J Cancer Res Ther; 2014 Nov; 10 Suppl():C195-200. PubMed ID: 25450281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. UGT1A1 polymorphisms in rectal cancer associated with the efficacy and toxicity of preoperative chemoradiotherapy using irinotecan.
    Kimura K; Yamano T; Igeta M; Imada A; Jihyung S; Babaya A; Hamanaka M; Kobayashi M; Tsukamoto K; Noda M; Ikeda M; Tomita N
    Cancer Sci; 2018 Dec; 109(12):3934-3942. PubMed ID: 30246377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients.
    Rouits E; Boisdron-Celle M; Dumont A; Guérin O; Morel A; Gamelin E
    Clin Cancer Res; 2004 Aug; 10(15):5151-9. PubMed ID: 15297419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UGT1A1 genotypes and glucuronidation of SN-38, the active metabolite of irinotecan.
    Ando Y; Saka H; Asai G; Sugiura S; Shimokata K; Kamataki T
    Ann Oncol; 1998 Aug; 9(8):845-7. PubMed ID: 9789606
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer.
    Li M; Wang Z; Guo J; Liu J; Li C; Liu L; Shi H; Liu L; Li H; Xie C; Zhang X; Sun W; Fang S; Bi X
    Onco Targets Ther; 2014; 7():1653-61. PubMed ID: 25285015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of UGT1A1 and ERCC1 gene polymorphisms with the outcome of combined irinotecan plus cisplatin treatment in recurrent ovarian cancer.
    Xu Q; Ding YY; Song LX; Xu JF
    Genet Mol Res; 2015 Jun; 14(2):7241-7. PubMed ID: 26125934
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.